NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

XMaster, I agree. with your comment:

I... believe it could be worth Billions.

Flaskworks, owned by NWBO, just submitted this to the WIPO:

WO2025106534 - PROCESSING INSTRUMENT FOR CELLULAR THERAPY MANUFACTURING
This patent was just applied for under WIPO which is: The World Intellectual Property Organization (WIPO), which is a specialized agency of the United Nations dedicated to promoting and protecting intellectual property (IP) globally. There are over 200 countries/regions that are part of WIPO.

#Flaskworks patent application submitted for a new invention - "Processing instrument for cellular therapy manufacturing" https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025106534…

Thanks to
@HenryMuney

Peter Davis, who brought Henry Muney's details of the new patent over to iHub, uses AI analysis to suggest what this patent can do for NWBO expanding products.

For example: AI analysis suggests

Contribution to the Broader Field of Cell Therapy:
Innovations in Flaskworks could set a benchmark for cell therapy manufacturing, benefiting other therapies like CAR-T cells or T-cell vaccines

T-cells are important for improving the efficacy (and memory?) of DCVax therapies, and I believe Roswell technology also focuses on developing T-cells.

Here's an important part of the patent as anaylized by Peter's AI search and points to easier transition and acceptance for use with other cancer types and other countries because of consistency across batches:

Improved Quality and Consistency:
Automated systems ensure greater precision in cell culture conditions, such as temperature, pH, and nutrient levels, leading to more consistent dendritic cell activation and potency. This is essential for maintaining therapeutic efficacy across batches, a key regulatory requirement
Consistency could also simplify regulatory submissions, as agencies like the FDA and EMA prioritize reproducible manufacturing processes.
Potential for Broader Application:
.Efficient manufacturing could support the development of DCVAX for other cancer types, such as ovarian or prostate cancer, where the company has previously conducted trials. This aligns with their strategy to build a "leading dendritic cell franchise," as noted in recent licensing deals